PD-L1 expression as a biomarker for nivolumab (NIVO) plus ipilimumab (IPI) and NIVO alone in advanced melanoma (MEL): A pooled analysis

被引：6

作者：

Long, G. V. ^{[1
]}

Larkin, J. ^{[2
]}

Ascierto, P. A. ^{[3
]}

Hodi, F. S. ^{[4
]}

Rutkowski, P. ^{[5
,6
]}

Sileni, V. ^{[7
]}

Hassel, J. ^{[8
]}

Lebbe, C. ^{[9
]}

Pavlick, A. C. ^{[10
]}

Wagstaff, J. ^{[11
]}

Schadendorf, D. ^{[12
]}

Dummer, R. ^{[13
]}

Hogg, D. ^{[14
]}

Haanen, J. B. A. G. ^{[15
]}

Corrie, P. ^{[16
]}

Hoeller, C. ^{[17
]}

Horak, C. ^{[18
]}

Wolchok, J. ^{[19
]}

Robert, C. ^{[20
,21
]}

机构：

[1] Melanoma Inst Australia, Med Oncol, Sydney, NSW, Australia

[2] Royal Marsden Hosp, Dept Med Oncol, London, England

[3] Fdn Pascale, Ist Nazl Tumori, Melanoma Canc Immunotherapy & Innovat Therapy Uni, Naples, Italy

[4] Dana Farber Canc Inst, Oncol, Boston, MA 02115 USA

[5] MSC Mem Canc Ctr, Oncol, Warsaw, Poland

[6] Inst Maria Sklodowska Curie, Warsaw, Poland

[7] Ist Oncol Veneto, Oncol, Padua, Italy

[8] Univ Heidelberg Hosp, Oncol, Heidelberg, Germany

[9] Hop St Louis, Dermatol, Paris, France

[10] NYU, Sch Med, Dept Med, New York, NY USA

[11] Singleton Hosp, South West Wales Canc Inst, Swansea, W Glam, Wales

[12] Univ Hosp Essen, Canc, Essen, Germany

[13] Univ Zurich Hosp, Dept Dermatol, Zurich, Switzerland

[14] Princess Margaret Hosp, Dept Med Oncol & Hematol, Toronto, ON, Canada

[15] Antoni van Leeuwenhoek Hosp, Dept Med Oncol, Netherlands Canc Inst, Amsterdam, Netherlands

[16] Univ Cambridge Hosp, Addenbrookes Hosp, Oncol Ctr, Cambridge, England

[17] Med Univ Wien, Dept Dermatol & Dermatooncol, Vienna, Austria

[18] BMS, Clin Biomarkers, Princeton, NJ USA

[19] Mem Sloan Kettering Canc Ctr, Ludwig Ctr, 1275 York Ave, New York, NY 10021 USA

[20] Gustave Roussy, Oncol, Villejuif, France

[21] Univ Paris Sud, Villejuif, France

来源：

ANNALS OF ONCOLOGY | 2016年 / 27卷

关键词：

D O I：

10.1093/annonc/mdw379.7

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1112PD

引用

页数：1